Blog

New eBook: Industry Insights on Rare Disease Research

By BBK on Tue, Apr 12, 2016



Our “Focus 5” eBook series, in which we share the insights of five thought leaders on a variety of industry topics and trends, has been incredibly well-received, and we’re pleased to issue the latest installment in the series on Rare Disease Research. Patient advocates, researchers and physicians from NORD, Xenon Pharmaceuticals, Landon Pediatric Foundation, Rare Genomics Institute and RareShare.org all weigh in on where we are today and what we can do to help advance research.

Topics: Patient Centricity, Rare Disease, clinical trials, Rare Disease Research

Thoughts from Rare Disease Day: Moving Forward and Raising the Patient Voice

By David Kerner on Thu, Mar 17, 2016

A few weeks ago, we attended NORD’s 7th Annual Rare Disease Day in Boston. People impacted by rare diseases, including patients and patient advocates, industry thought leaders and legislators, gathered at the State House to help raise awareness of the impact rare diseases have on the lives of millions of people in the US and around the world.

Topics: Patient Centricity, Rare Disease, clinical trials

RSG® Arrive: Patient Travel Program Takes Patient-Centric Approach

By BBK on Tue, Aug 18, 2015

Last week on the blog we highlighted BBK’s RSG® Arrive service, which underscores our commitment to patient centricity by easing study visit travel complexities and in turn, expanding clinical research participation. We know that travel can be a hassle, but what if getting a patient to a site could mean the difference between receiving a potentially life-saving treatment or not? What makes a patient travel program such an integral part of the clinical trial landscape?

Topics: Patient Centricity, Patient Travel

BBK and The Diabetes Collective Talk the Future of Patient Centricity

By BBKWorldwide on Thu, Aug 13, 2015

Topics: Patient Centricity

Raising the Patient Voice, Insights from the Michael J. Fox Foundation and BBK

By BBKWorldwide on Tue, Aug 11, 2015

At the 2015 DIA Annual Meeting in June, we sat down PharmaVOICE Editor Taren Grom and Claire Meunier, Vice President of Research Engagement at the Michael J. Fox Foundation for a conversation about patient centricity and the role technology is playing and will continue to play as we move forward.

Topics: Patient Centricity, Technology

Key Takeaways from 51st Annual DIA Meeting

By BBKWorldwide on Tue, Jun 30, 2015

With another successful DIA Annual Meeting behind us, as well as some time to reflect, we wanted to thank our industry partners and colleagues for making this year’s meeting one of the best yet. We also want to highlight some of the thought-provoking work and innovations that raised the already high bar. Here goes.

Topics: Patient Centricity

Are You Patient Centric? Learn Why you Should be from BBK at DIA

By BBK Worldwide on Tue, May 26, 2015

BBK Worldwide is excited to be leading two Innovation Theater panels at this year’s DIA event, taking place June 14-18 in Washington, DC. BBK Co-Founder Bonnie A. Brescia will lead our first discussion on Monday, June 15 from 4:15-4:45 p.m. with Claire Meunier, VP, Research Engagement with The Michael J. Fox Foundation and Christel Aprigliano, CEO of the Diabetes Collective.

Topics: Patient Centricity

BBK Talks Patient Centricity, mHealth, Rare Disease & more at DIA 2015

By BBK Worldwide on Wed, May 13, 2015

BBK Worldwide is once again looking forward to attending Drug Information Association 2015 (DIA), which this year will take place from June 15 - 18 at the Walter E. Washington Convention Center in DC. We always love attending this annual event – the industry’s largest, which attracts more than 7,000 attendees each year. DIA provides a global, unbiased platform to raise the level of discussion to facilitate innovation that will change the future of healthcare.  

Topics: Patient Centricity, mHealth, Rare Disease

BBK’s Take: Draft Bill to Accelerate 21st Century Cures

By Bonnie A. Brescia on Thu, Apr 30, 2015

During the first 25 years of the Orphan Drug Act (passed in 1983), only 326 new drugs were approved by the FDA and brought to market for all rare disease patients combined. Prior to the Orphan Drug Act, fewer than 10 treatments had been developed by industry for rare diseases. This is progress however; there is a lot of work to be done.

Topics: Patient Centricity, 21st Century Cures

Throw-back Thursday: Patient Centricity 13 years later

By Bonnie A. Brescia on Thu, Mar 12, 2015

You know the feeling. You believe strongly in an idea that hasn’t yet hit the mainstream. You talk it up, write about it, join a march, advocate for it, and sometimes even beg people to give the concept a try. So here we are. Patient centricity in clinical research has hit the mainstream. There is no conference that doesn’t include the topic on the agenda – and many have absorbed it into their meeting titles and promotional materials. No group of clinical trial professionals gets around a table or on a conference call without at least three people using the phrase “patient centric” during the discussion. Some companies even require that clinical teams incorporate patient centricity into their study design. Great progress, you say.

Topics: Patient Centricity

 

Subscribe Our Blog